Guna Muppuri, CEO of Indies Pharma Jamaica Limited (Gleaner photo)
Drug company Indies Pharma Jamaica Limited is looking to double next year's revenues.
The move follows approval of its abbreviated new drug application, referred to as ANDA or, more simply, generic drug, by the Food and Drug Administration of the United States, three months earlier than expected.
Indies Pharma applied to the FDA in January 2023, for which a decision was expected in November, but received approval on August 22 for a generic version of a drug that treats heart disease.
Last year, Indies Pharma recorded total revenue of $1.6 billion or approximately US$6.72 million for its financial year ending October 2023.
comments powered by Disqus
All feeds
